Evidence map›Paper›PMID 23299381›Full record

ArticleThe journal of nutrition, health & aging2013

Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement.

H Hampel, S Lista

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of nutrition, health & aging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Dietary tributyrin supplementation in Parkinson's disease: An open-label target engagement study.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  2. Review
  3. Biomarkers and Precision Medicine in Alzheimer's Disease.Advances in experimental medicine and biology · 2021
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Rethinking on the concept of biomarkers in preclinical Alzheimer's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2016
    Review
  10. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2016
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Amyloid imaging in Alzheimer's disease: a literature review.The journal of nutrition, health & aging · 2014
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

H HampelDepartment of Psychiatry, Goethe-University of Frankfurt, Frankfurt am Main, Germany. harald.hampel@med.uni-muenchen.de
S Lista

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidisciplinary basic research led to an evolving knowledge of the molecular pathogenesis of Alzheimer's disease (AD). These advances have been translated into defined therapeutic concepts and distinct classes of compounds with putative disease-modifying effects that are now being tested in clinical trials. There is a growing consensus that disease-modifying treatments may be most effective when commenced early in the course and progression of AD pathophysiology, before amyloid deposition and neurodegeneration become too widespread. Biological indicators of pathophysiological mechanisms are required to chart and identify AD in the prodromal phase or, preferably, in asymptomatic individuals. Biomarkers are becoming even more important, owing to the challenges in demonstrating efficacy of candidate-drugs that hit pathophysiological targets using clinical and cognitive outcomes in early AD trials with limited duration. Currently, there is emerging consensus that advances in therapeutic strategies for AD that delay predefined milestones or slow the cognitive and disease progression would considerably decrease the expanding global burden of the disease. To effectively test preventive compounds for AD and bring therapy to affected individuals as early as possible there is an urgent need for a concerted collaboration among worldwide academic institutions, industry, and regulatory bodies with the aim of establishing networks for the identification and qualification of multi-modal biological disease markers.

Indexed as

Alzheimer DiseaseBiomarkersDisease ProgressionHumansNeuroimagingBiomarkers

Identifiers

PMID23299381
PMCPMC12879680

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.